FTC Expands Reporting Requirements for Transfers of Pharmaceutical Patent Rights
|November 13, 2013|
Previously published on November 11, 2013
The U.S. Federal Trade Commission ("FTC") issued final changes to the premerger notification rules that affect whether pharmaceutical companies must report certain proposed acquisitions of exclusive patent rights to the FTC and the Antitrust Division of the Department of Justice ("DOJ") for antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). The final rules apply solely to the pharmaceutical industry and will become effective 30 days after their publication in the Federal Register. The amendments do not change the current HSR reporting requirements related to exclusive licenses in other industries.
The views expressed in this document are solely the views of the author and not Martindale-Hubbell. This document is intended for informational purposes only and is not legal advice or a substitute for consultation with a licensed legal professional in a particular case or circumstance.
View More Library Documents By...
|Cadwalader Wickersham Taft LLP Overview|